New avenues for Parkinson's disease therapeutics: disease-modifying strategies based on the gut microbiota
Open accessThe DOI matches its Crossref record; 365 of the 366 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is a multifactorial neurodegenerative disorder that currently affects 1% of the population over the age of 60 years, and for which no disease-modifying treatments exist. Neurodegeneration and neuropathology in different brain areas are manifested as both motor and non-motor symptoms in patients. Recent interest in the gut-brain axis has led to increasing research into the gut microbiota changes in PD patients and their impact on disease pathophysiology. As evidence is piling up on the effects of gut microbiota in disease development and progression, another front of action has opened up in relation to the potential usage of microbiota-based therapeutic strategies in treating gastrointestinal alterations and possibly also motor symptoms in PD. This review provides status on the different strategies that are in the front line (i.e., antibiotics; probiotics; prebiotics; synbiotics; dietary interventions; fecal microbiota transplantation, live biotherapeutic products), and discusses the opportunities and challenges the field of microbiome research in PD is facing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It appears that the Parkinson's disease-related gut dysbiosis is associated with the imbalance of SCFAs-producing bacteria (Prevotellaceae, Faecalibacterium, and Ruminococcaceae), bacteria that participate in lipid metabolism (e.g., Christensenellaceae) and those controlling gut permeability (e.g., Verrucomicrobiaceae, Akkermansia) [418,419,445].”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [445]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“An important observation is that human gut microbiota metabolizes levodopa and thereby may affect its bioavailability and efficacy.”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [445]
In the citing paper
“Identification of bacteria that metabolize levodopa to dopamine (Enterococcus faecalis) and dopamine to m-tyramine (Eggerthella lenta) [445]”
From The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders (2021) · cites this paper as [445]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Tamtaji, O. R., Taghizadeh, M., Daneshvar Kakhaki, R., Kouchaki, E., Bahmani, F., Borzabadi, S., Oryan, S., Mafi, A., & Asemi, Z. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.05.018 · Cited by 398 · cited 2×
“Lactobacillus acidophilus, Bifidobacterium bifigum, Lactobacillus reuteri and Lactobacillus fermentum (capsules) 8 × 109 CFU 1X a day for 12 weeks PD patients • Decreased MDS-UPDRS scores [253]”
BackgroundMethodRetractedRetracted: Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease
Heinzel, S., Aho, V. T. E., Suenkel, U., von Thaler, A., Schulte, C., Deuschle, C., Paulin, L., Hantunen, S., Brockmann, K., Eschweiler, G. W., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25788 · Cited by 95
RetractedHill (2014) · doi:10.1038/nrgastro.2014.66 · Cited by 9,592 · cited 1×
“Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit to the host [236].”
BackgroundHuman gut microbiome viewed across age and geography
Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., Magris, M., Hidalgo, G., Baldassano, R. N., Anokhin, A. P., et al. (2012) · Nature · doi:10.1038/nature11053 · Cited by 7,815
Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics
Gibson, G. R., & Roberfroid, M. B. (1995) · The Journal of Nutrition · doi:10.1093/jn/125.6.1401 · Cited by 7,667
Enterotypes of the human gut microbiome
MetaHIT Consortium (additional members), Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D. R., Fernandes, G. R., Tap, J., Bruls, T., et al. (2011) · Nature · doi:10.1038/nature09944 · Cited by 7,548
Molecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin
Aziz, J., Shezali, H., Radzi, Z., Yahya, N. A., Abu Kassim, N. H., Czernuszka, J., & Rahman, M. T. (2016) · Skin Pharmacology and Physiology · doi:10.1159/000447017 · Cited by 7,323
From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites
Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016) · Cell · doi:10.1016/j.cell.2016.05.041 · Cited by 7,070 · cited 1×
“Moreover, they induce the expression of anti-inflammatory cytokines and suppress the expression of the pro-inflamatory ones [128,129].”
BackgroundInflamm‐aging: An Evolutionary Perspective on Immunosenescence
FRANCESCHI, C., BONAFÈ, M., VALENSIN, S., OLIVIERI, F., DE LUCA, M., OTTAVIANI, E., & DE BENEDICTIS, G. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06651.x · Cited by 5,358 · cited 1×
“This contributes to the deterioration of the neuro-immune system in a process called immunosenescence [157] and is directly related with inflammaging [158,159].”
BackgroundMind-altering microorganisms: the impact of the gut microbiota on brain and behaviour
Cryan, J. F., & Dinan, T. G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3346 · Cited by 4,572
Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity
Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J. P., Druart, C., Bindels, L. B., Guiot, Y., Derrien, M., Muccioli, G. G., Delzenne, N. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219451110 · Cited by 4,511
Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humarán, L. G., Gratadoux, J.-J., Blugeon, S., Bridonneau, C., Furet, J.-P., Corthier, G., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804812105 · Cited by 4,413 · cited 1×
“Prevotellaceace and Lachnospiraceae family members, as well as the genus Blautia, Roseburia, and Faecalibacterium, which are reduced in PD, are commensals involved in the mucus formation of the gut mucosal layer and in the production of short chain fatty acids (SCFAs) [109,121,122].”
BackgroundInteraction between microbiota and immunity in health and disease
Zheng, D., Liwinski, T., & Elinav, E. (2020) · Cell Research · doi:10.1038/s41422-020-0332-7 · Cited by 3,947 · cited 1×
“Gut microbiota activity is completely linked to the status of the intestinal immune system [174].”
BackgroundParada Venegas, D., De la Fuente, M. K., Landskron, G., González, M. J., Quera, R., Dijkstra, G., Harmsen, H. J. M., Faber, K. N., & Hermoso, M. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00277 · Cited by 3,820 · cited 2×
“Another set of key mediators in the brain–gut immune communication are SCFA, which have anti-oxidant and anti-inflammatory properties that may affect the intestinal mucosal immunity, the peripheral immune system and also modulate central neuroimmune brain function [121,181].”
BackgroundGut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622 · cited 2×
“Thirdly, data from experimental animal models support the idea that gut dysbiosis, caused by intestinal infection or environmental toxins, among other possible causes, may act as a triggering event in PD development and/or progression An in vivo study using α-syn overexpressing mice reported that gut microbiota is inv…”
BackgroundIntroduction to the human gut microbiota
Thursby, E., & Juge, N. (2017) · Biochemical Journal · doi:10.1042/bcj20160510 · Cited by 3,600 · cited 1×
“Inside the GI tract, a complex ecological community called the gut microbiota exists and is composed by more than 100 trillion of microorganisms of several species [41].”
BackgroundHost microbiota constantly control maturation and function of microglia in the CNS
Erny, D., Hrabě de Angelis, A. L., Jaitin, D., Wieghofer, P., Staszewski, O., David, E., Keren-Shaul, H., Mahlakoiv, T., Jakobshagen, K., Buch, T., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4030 · Cited by 3,569 · cited 1×
“However, the introduction of external substances or pathogens and gut dysbiosis can both lead to increased gut inflammation, thus affecting intestinal homeostasis and altering CNS function via the release of neurotransmitters and cytokines [173,176,177].”
BackgroundRinninella, E., Raoul, P., Cintoni, M., Franceschi, F., Miggiano, G. A. D., Gasbarrini, A., & Mele, M. C. (2019) · Microorganisms · doi:10.3390/microorganisms7010014 · Cited by 3,462 · cited 1×
“It offers many benefits to the host through a wide range of physiological functions such as nutrients and metabolites absorption and synthesis [42], protection against pathogens [43], and regulation of host immunity [44], as well as integrity of the intestinal epithelium.”
BackgroundGut microbiota, metabolites and host immunity
Rooks, M. G., & Garrett, W. S. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.42 · Cited by 3,409 · cited 1×
“SCFAs, the major ones being butyrate, propionate, and acetate, are microbial metabolites that constitute the major products from bacterial fermentation of dietary fibers in the intestines [123,124] and are considered key candidate mediators [125].”
BackgroundThe role of short-chain fatty acids in microbiota–gut–brain communication
Dalile, B., Van Oudenhove, L., Vervliet, B., & Verbeke, K. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0157-3 · Cited by 3,357 · cited 1×
“Another set of key mediators in the brain–gut immune communication are SCFA, which have anti-oxidant and anti-inflammatory properties that may affect the intestinal mucosal immunity, the peripheral immune system and also modulate central neuroimmune brain function [121,181].”
BackgroundThe Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication
Silva, Y. P., Bernardi, A., & Frozza, R. L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00025 · Cited by 3,043 · cited 2×
“SCFAs, the major ones being butyrate, propionate, and acetate, are microbial metabolites that constitute the major products from bacterial fermentation of dietary fibers in the intestines [123,124] and are considered key candidate mediators [125].”
BackgroundLuk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563
The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems.
(2015) · PubMed Central · Cited by 2,540
The gut microbiota influences blood-brain barrier permeability in mice
Braniste, V., Al-Asmakh, M., Kowal, C., Anuar, F., Abbaspour, A., Tóth, M., Korecka, A., Bakocevic, N., Ng, L. G., Kundu, P., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009759 · Cited by 2,530 · cited 1×
“Moreover, they serve as energy substrate for intestinal epithelial cells [182] and have also been shown to reinforce the integrity of the blood–brain barrier (BBB) in mice [183].”
BackgroundThe impact of dietary fiber on gut microbiota in host health and disease
Makki, K., Deehan, E. C., Walter, J., & Bäckhed, F. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.05.012 · Cited by 2,517
Epidemiology of Parkinson’s disease
Tysnes, O.-B., & Storstein, A. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1686-y · Cited by 2,414
Effects of probiotics, prebiotics, and synbiotics on human health
Markowiak, P., & Śliżewska, K. (2017) · Nutrients · doi:10.3390/nu9091021 · Cited by 2,401
The prevalence of Parkinson's disease: a systematic review and meta-analysis
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014) · Movement Disorders · doi:10.1002/mds.25945 · Cited by 2,188 · cited 1×
“Parkinson’s disease (PD) is the second most common chronic, progressive neurodegenerative disorder after Alzheimer’s disease (AD), affecting 1% of the population over the age of 60 years [1,2].”
BackgroundThe gut microbiota–brain axis in behaviour and brain disorders
Morais, L. H., Schreiber, H. L., & Mazmanian, S. K. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00460-0 · Cited by 2,149
Peng, L., Li, Z.-R., Green, R. S., Holzmanr, I. R., & Lin, J. (2009) · The Journal of Nutrition · doi:10.3945/jn.109.104638 · Cited by 2,130 · cited 1×
“Moreover, they serve as energy substrate for intestinal epithelial cells [182] and have also been shown to reinforce the integrity of the blood–brain barrier (BBB) in mice [183].”
BackgroundPrebiotic effects: metabolic and health benefits
Roberfroid, M., Gibson, G. R., Hoyles, L., McCartney, A. L., Rastall, R., Rowland, I., Wolvers, D., Watzl, B., Szajewska, H., Stahl, B., et al. (2010) · British Journal of Nutrition · doi:10.1017/s0007114510003363 · Cited by 2,085
Machine learning applications in genetics and genomics
Libbrecht, M. W., & Noble, W. S. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3920 · Cited by 2,084
How colonization by microbiota in early life shapes the immune system
Gensollen, T., Iyer, S. S., Kasper, D. L., & Blumberg, R. S. (2016) · Science · doi:10.1126/science.aad9378 · Cited by 2,044 · cited 1×
“It offers many benefits to the host through a wide range of physiological functions such as nutrients and metabolites absorption and synthesis [42], protection against pathogens [43], and regulation of host immunity [44], as well as integrity of the intestinal epithelium.”
BackgroundGut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968 · cited 3×
“Bacteroidetes Prevotellaceae Prevotella 3 5 [24,60,95,98,100,107,110,111]”
BackgroundLloyd-Price, J., Abu-Ali, G., & Huttenhower, C. (2016) · Genome Medicine · doi:10.1186/s13073-016-0307-y · Cited by 1,891 · cited 1×
“Although there is still no consensus on the composition of a healthy gut microbiota, it seems that the more diverse and balanced the gut microbiota is, the more it has the ability to resist perturbations or to recover towards a healthy state more easily [47].”
BackgroundLi, J.-Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., Lashley, T., Quinn, N. P., Rehncrona, S., Björklund, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1746 · Cited by 1,845
Composition, variability, and temporal stability of the intestinal microbiota of the elderly
Claesson, M. J., Cusack, S., O'Sullivan, O., Greene-Diniz, R., de Weerd, H., Flannery, E., Marchesi, J. R., Falush, D., Dinan, T., Fitzgerald, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000097107 · Cited by 1,754 · cited 1×
“Elder people have different gut microbiota compared with healthy adults and this difference can be attributed to several causes such as lifestyle, medications, infections, organ dysfunctions, diseases, and other related factors [45,155].”
BackgroundNon-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
Chaudhuri, K. R., & Schapira, A. H. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70068-7 · Cited by 1,738 · cited 1×
“In the past 15 years, non-motor PD symptoms have raised a lot of attention because they can occur years before the onset of motor symptoms [16,17].”
BackgroundBraak, H., R�b, U., Gai, W. P., & Del Tredici, K. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-002-0808-2 · Cited by 1,683 · cited 2×
“This hypothesis is supported by data from rodent and non-human primate experimental models [69], where different forms of α-syn were transported via the vagus nerve and reached the DMNV in the brainstem after injection into the intestinal wall [66,70–74].”
BackgroundKelly, J. R., Borre, Y., O' Brien, C., Patterson, E., El Aidy, S., Deane, J., Kennedy, P. J., Beers, S., Scott, K., Moloney, G., et al. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.07.019 · Cited by 1,683
Odamaki, T., Kato, K., Sugahara, H., Hashikura, N., Takahashi, S., Xiao, J.-Z., Abe, F., & Osawa, R. (2016) · BMC Microbiology · doi:10.1186/s12866-016-0708-5 · Cited by 1,521
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518 · cited 1×
“CTX is known to increase glutamate transporter subtype 1 (GLT-1) expression and could thus be a feasible venue to increase glutamate uptake and reduce excitotoxicity [222].”
BackgroundInhibition of Histone Deacetylase Activity by Butyrate
Davie, J. R. (2003) · The Journal of Nutrition · doi:10.1093/jn/133.7.2485s · Cited by 1,515
Interactions between the microbiota and pathogenic bacteria in the gut
Bäumler, A. J., & Sperandio, V. (2016) · Nature · doi:10.1038/nature18849 · Cited by 1,420 · cited 2×
“It offers many benefits to the host through a wide range of physiological functions such as nutrients and metabolites absorption and synthesis [42], protection against pathogens [43], and regulation of host immunity [44], as well as integrity of the intestinal epithelium.”
BackgroundThe pros, cons, and many unknowns of probiotics
Suez, J., Zmora, N., Segal, E., & Elinav, E. (2019) · Nature Medicine · doi:10.1038/s41591-019-0439-x · Cited by 1,398 · cited 1×
“However, even if they seem beneficial for the healthy population, they may act as opportunistic pathogens and cause infection in immune-compromised individuals [111,148].”
BackgroundThe vagus nerve at the interface of the microbiota-gut-brain axis
Bonaz, B., Bazin, T., & Pellissier, S. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00049 · Cited by 1,397 · cited 1×
“In a broader sense, it includes the neuroendocrine and neuroimmune systems, including the hypothalamic–pituitary– adrenal axis (HPA axis), sympathetic and parasympathetic arms of the autonomic nervous system (ANS), including the ENS and the vagus nerve, and the gut microbiota [57,58].”
BackgroundKim, S., Kwon, S.-H., Kam, T.-I., Panicker, N., Karuppagounder, S. S., Lee, S., Lee, J. H., Kim, W. R., Kook, M., Foss, C. A., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.05.035 · Cited by 1,397
Potential beneficial effects of butyrate in intestinal and extraintestinal diseases
Canani, R. B. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i12.1519 · Cited by 1,381
Genetics of Parkinson's Disease
Klein, C., & Westenberger, A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a008888 · Cited by 1,358
The gut microbiome in neurological disorders
Cryan, J. F., O'Riordan, K. J., Sandhu, K., Peterson, V., & Dinan, T. G. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30356-4 · Cited by 1,336
Lupp, C., Robertson, M. L., Wickham, M. E., Sekirov, I., Champion, O. L., Gaynor, E. C., & Finlay, B. B. (2007) · Cell Host & Microbe · doi:10.1016/j.chom.2007.06.010 · Cited by 1,307 · cited 1×
“This family is among the most commonly overgrown bacteria in many conditions involving gut inflammation [140,141] as they are responsible for the production of the endotoxins lipopolysaccharides (LPS) [142].”
BackgroundMelanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301 · cited 1×
“regions has also been reported [28–30], preferentially occurring within neurons that contain the dark-brown cytoplasmic pigment neuromelanin (NM) [29,31].”
BackgroundProbiotics, prebiotics and synbiotics- a review
Pandey, K. R., Naik, S. R., & Vakil, B. V. (2015) · Journal of Food Science and Technology · doi:10.1007/s13197-015-1921-1 · Cited by 1,291
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281 · cited 2×
“Verrucomicrobia Verrucomicrobiaceae 8 0 [60,98,101,103,105,106,109,119]”
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183 · cited 1×
“Another study also reported that minocycline prevented MPTP-induced activation of microglia, the formation of IL-1β, and the activation of NADPH–oxidase and iNOS [211].”
BackgroundUnger, M. M., Spiegel, J., Dillmann, K.-U., Grundmann, D., Philippeit, H., Bürmann, J., Faßbender, K., Schwiertz, A., & Schäfer, K.-H. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.08.019 · Cited by 1,159 · cited 3×
“Correlating with gut microbiota reductions, fecal SCFA concentrations are also reduced in PD patients compared to HC [97].”
BackgroundHemarajata, P., & Versalovic, J. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12459294 · Cited by 1,083 · cited 1×
“Metagenomic, metatranscriptomic, and metabolomics will be very valuable tools to globally examine interactions between probiotics, intestinal microbes, and the mammalian GI tract [255].”
BackgroundPerlmutter, J. S., & Mink, J. W. (2006) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.29.051605.112824 · Cited by 1,073
Psychobiotics and the manipulation of bacteria–gut–brain signals
Sarkar, A., Lehto, S. M., Harty, S., Dinan, T. G., Cryan, J. F., & Burnet, P. W. J. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.09.002 · Cited by 1,068
Probiotics, Prebiotics, and Synbiotics
de Vrese, M., & Schrezenmeir, J. (2008) · Advances in Biochemical Engineering/Biotechnology · doi:10.1007/10_2008_097 · Cited by 1,028
Parkinson's disease: a dual‐hit hypothesis
Hawkes, C. H., Del Tredici, K., & Braak, H. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00874.x · Cited by 1,021 · cited 2×
“This hypothesis is supported by data from rodent and non-human primate experimental models [69], where different forms of α-syn were transported via the vagus nerve and reached the DMNV in the brainstem after injection into the intestinal wall [66,70–74].”
BackgroundGastrointestinal Dysfunction in Parkinson’s Disease
Fasano, A., Visanji, N. P., Liu, L. W. C., Lang, A. E., & Pfeiffer, R. F. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00007-1 · Cited by 1,016
Clinical progression in Parkinson disease and the neurobiology of axons
Cheng, H., Ulane, C. M., & Burke, R. E. (2010) · Annals of Neurology · doi:10.1002/ana.21995 · Cited by 1,012 · cited 1×
“, rigidity, movement slowness, resting tremor, among others [4–6]), which is first noticeable when there is already 40–60% neuronal loss in the substantia nigra (SN) [7,8].”
BackgroundForsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., Estes, J. D., Dodiya, H. B., & Keshavarzian, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028032 · Cited by 974 · cited 1×
“Interestingly, some studies report alterations in the intestinal epithelial barrier [169,170] and the presence”
BackgroundDyall, S. C. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00052 · Cited by 943
Health Benefits of Probiotics: A Review
Kechagia, M., Basoulis, D., Konstantopoulou, S., Dimitriadi, D., Gyftopoulou, K., Skarmoutsou, N., & Fakiri, E. M. (2013) · ISRN Nutrition · doi:10.5402/2013/481651 · Cited by 938
Minocycline: Far beyond an Antibiotic
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12139 · Cited by 935 · cited 1×
“Together, the available studies suggest that minocycline inhibits microglial activation through p38 MAPK pathway, which regulates the release of pro-inflammatory factors from activated microglia [213,214].”
BackgroundDeMaagd, G. A., & Philip, A. (2015) · PubMed · Cited by 926
Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats
Holmqvist, S., Chutna, O., Bousset, L., Aldrin-Kirk, P., Li, W., Björklund, T., Wang, Z.-Y., Roybon, L., Melki, R., & Li, J.-Y. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1343-6 · Cited by 925 · cited 1×
“Several pieces of evidence have led to the hypothesis that GI dysfunction is a contributor to PD, the GI tract being in close connection to the environment and a gateway system to the brain [21,66].”
BackgroundGastrointestinal dysfunction in Parkinson's disease
Pfeiffer, R. F. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00307-7 · Cited by 925
Probiotics and the gut microbiota in intestinal health and disease
Gareau, M. G., Sherman, P. M., & Walker, W. A. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.117 · Cited by 907 · cited 1×
“The increased levels of the families Lactobacillaceae and Bifidobacteriaceae in PD seem ironical, as they are usually well recognized as probiotics [23,144], and they are used in some clinical trials to treat constipation [145] and to reduce bloating and abdominal pain [146].”
BackgroundNeuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice
Zhao, J., Bi, W., Xiao, S., Lan, X., Cheng, X., Zhang, J., Lu, D., Wei, W., Wang, Y., Li, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42286-8 · Cited by 896 · cited 11×
“The presence of LPS disrupts gut homeostasis inducing the production of pro-inflammatory cytokines that may produce an inflammatory response in the CNS [143].”
BackgroundInfluentialNeuroinflammation in Parkinson's disease and its potential as therapeutic target
Wang, Q., Liu, Y., & Zhou, J. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0042-0 · Cited by 884
Mechanisms of inflammation-driven bacterial dysbiosis in the gut
Zeng, M. Y., Inohara, N., & Nuñez, G. (2017) · Mucosal Immunology · doi:10.1038/mi.2016.75 · Cited by 877 · cited 1×
“Enterobacteriaceae are a large family of gram-negative bacteria residing in the gut at low levels and localized closely to the mucosal epithelium [139].”
BackgroundHill‐Burns, E. M., Debelius, J. W., Morton, J. T., Wissemann, W. T., Lewis, M. R., Wallen, Z. D., Peddada, S. D., Factor, S. A., Molho, E., Zabetian, C. P., et al. (2017) · Movement Disorders · doi:10.1002/mds.26942 · Cited by 874 · cited 6×
“Actinobacteria Bifidobacteriaceae 5 0 [98,103,104,107,119]”
InfluentialParkinson's Disease and Parkinsonism: Neuropathology
Dickson, D. W. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009258 · Cited by 847
Brain-Gut-Microbiota Axis in Alzheimer’s Disease
Kowalski, K., & Mulak, A. (2019) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18087 · Cited by 826 · cited 1×
“On the other hand, it has been shown that alterations in gut microbiota composition and function can lead to dysbiosis, which has been linked to the etiology of multiples GI [51] and non-GI diseases such as anxiety, depression [52], autism [53], spectrum disorders [54], AD [55], and for the interest of this review, PD…”
BackgroundVagotomy and subsequent risk of Parkinson's disease
Svensson, E., Horváth‐Puhó, E., Thomsen, R. W., Djurhuus, J. C., Pedersen, L., Borghammer, P., & Sørensen, H. T. (2015) · Annals of Neurology · doi:10.1002/ana.24448 · Cited by 806 · cited 1×
“Secondly, there is epidemiological evidence from a Danish study reporting that full truncal vagotomy decreased the risk of developing PD [89], although they did not differentiate truncal from selective vagotomy.”
BackgroundDu, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L. G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251341998 · Cited by 789 · cited 4×
“One study reported that rifampicin inhibited the production of proinflammatory factors such as iNOs, IL-1β, and TNF-α by downregulating nuclear factor-kappa B (NF-kB) and MAPK pathway from microglial cells [233].”
BackgroundInfluentialDiscovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism
Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J., & Balskus, E. P. (2019) · Science · doi:10.1126/science.aau6323 · Cited by 753 · cited 20×
“Related with this study, a different group described another possible pathway for gut bacterial L-dopa metabolism.”
BackgroundInfluentialLong-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota
Kang, D.-W., Adams, J. B., Coleman, D. M., Pollard, E. L., Maldonado, J., McDonough-Means, S., Caporaso, J. G., & Krajmalnik-Brown, R. (2019) · Scientific Reports · doi:10.1038/s41598-019-42183-0 · Cited by 749 · cited 1×
“On the other hand, it has been shown that alterations in gut microbiota composition and function can lead to dysbiosis, which has been linked to the etiology of multiples GI [51] and non-GI diseases such as anxiety, depression [52], autism [53], spectrum disorders [54], AD [55], and for the interest of this review, PD…”
BackgroundSun, M.-F., Zhu, Y.-L., Zhou, Z.-L., Jia, X.-B., Xu, Y.-D., Yang, Q., Cui, C., & Shen, Y.-Q. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.02.005 · Cited by 736 · cited 1×
“Consistent with these findings, another study also showed that fecal microbiota transplants (FMT) from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated PD mice into wild type mice induced impaired motor function and decreased striatal dopamine [92].”
ResultThe microbial pharmacists within us: a metagenomic view of xenobiotic metabolism
Spanogiannopoulos, P., Bess, E. N., Carmody, R. N., & Turnbaugh, P. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.17 · Cited by 717 · cited 2×
“It is known that the gut microbiota can influence the metabolism of different drugs, in many cases changing their efficacy and/or side effect profiles [258].”
BackgroundMahul-Mellier, A.-L., Burtscher, J., Maharjan, N., Weerens, L., Croisier, M., Kuttler, F., Leleu, M., Knott, G. W., & Lashuel, H. A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913904117 · Cited by 710 · cited 1×
“However, the molecular and cellular processes that trigger the misfolding, fibrillization, LB formation, and spread of α-syn in the brain remain poorly understood [33].”
BackgroundAkkermansia muciniphila is a promising probiotic
Zhang, T., Li, Q., Cheng, L., Buch, H., & Zhang, F. (2019) · Microbial Biotechnology · doi:10.1111/1751-7915.13410 · Cited by 708 · cited 1×
“is being considered a good probiotic [137,138], the maintenance of steady state levels of Akkermansia may be a pre-requisite for gut homeostasis.”
BackgroundCollado, M. C., Derrien, M., Isolauri, E., de Vos, W. M., & Salminen, S. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.01477-07 · Cited by 706 · cited 1×
“muciniphila), a gram-negative bacteria located mainly in the mucus layer of the intestinal epithelium and producing mucin-degrading enzymes, that has an important role in maintaining intestinal barrier homeostasis and exerts competitive inhibition on other pathogenic bacteria that degrade the mucin [130,131].”
BackgroundAbreu, M. T., Vora, P., Faure, E., Thomas, L. S., Arnold, E. T., & Arditi, M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1609 · Cited by 680 · cited 1×
“Toll-Like receptors (TLR) are innate immune receptors expressed in intestinal epithelial cells, ENS cells and microglia [178] that play a fundamental role in promoting the release of pro-inflammatory cytokines in response to various components from bacteria including peptidoglycans and lipoproteins (TLR2) and LPS on t…”
BackgroundGut microbiome and aging: physiological and mechanistic insights
Nagpal, R., Mainali, R., Ahmadi, S., Wang, S., Singh, R., Kavanagh, K., Kitzman, D. W., Kushugulova, A., Marotta, F., & Yadav, H. (2018) · Nutrition and Healthy Aging · doi:10.3233/nha-170030 · Cited by 670 · cited 2×
“The gut microbiota is established at birth and keeps developing and fluctuating in composition until the adult life, where it is found to be relatively stable [45].”
BackgroundAntibiotics and the Gut Microbiota
Modi, S. R., Collins, J. J., & Relman, D. A. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72333 · Cited by 667 · cited 1×
“Thus, it is important to understand the biology, the properties, and the relations between the coexisting species and how they interact with the host to be able to design new therapeutic approaches while preserving and protecting the beneficial bacteria of our gut microbiota [208].”
BackgroundThe current and projected economic burden of Parkinson's disease in the United States
Kowal, S. L., Dall, T. M., Chakrabarti, R., Storm, M. V., & Jain, A. (2013) · Movement Disorders · doi:10.1002/mds.25292 · Cited by 667 · cited 1×
“PD is currently affecting nearly seven to ten million people worldwide and the incidence and prevalence of PD is expected to increase substantially in the next decades due to the increase in life expectancy that our society has experienced [3].”
BackgroundBedarf, J. R., Hildebrand, F., Coelho, L. P., Sunagawa, S., Bahram, M., Goeser, F., Bork, P., & Wüllner, U. (2017) · Genome Medicine · doi:10.1186/s13073-017-0428-y · Cited by 642 · cited 3×
“Verrucomicrobia Verrucomicrobiaceae 8 0 [60,98,101,103,105,106,109,119]”
BackgroundRecasens, A., Dehay, B., Bové, J., Carballo‐Carbajal, I., Dovero, S., Pérez‐Villalba, A., Fernagut, P., Blesa, J., Parent, A., Perier, C., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24066 · Cited by 632
Colonic inflammation in Parkinson's disease
Devos, D., Lebouvier, T., Lardeux, B., Biraud, M., Rouaud, T., Pouclet, H., Coron, E., Bruley des Varannes, S., Naveilhan, P., Nguyen, J.-M., et al. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.09.007 · Cited by 627 · cited 1×
“of chronic intestinal inflammation in some PD patients [171,172] leading to the hypothesis that intestinal and peripheral inflammation contribute to neuroinflammation aggravating the progression of the disease [173].”
BackgroundPro- and anti-inflammatory effects of short chain fatty acids on immune and endothelial cells
Li, M., van Esch, B. C. A. M., Wagenaar, G. T. M., Garssen, J., Folkerts, G., & Henricks, P. A. J. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.05.003 · Cited by 614 · cited 1×
“For further information on this controversy, please refer to reviews discussing specifically the role of SCFAs in inflammation regulation [125,186].”
BackgroundGut Microbiota’s Effect on Mental Health: The Gut-Brain Axis
Clapp, M., Aurora, N., Herrera, L., Bhatia, M., Wilen, E., & Wakefield, S. (2017) · Clinics and Practice · doi:10.4081/cp.2017.987 · Cited by 608 · cited 1×
“On the other hand, it has been shown that alterations in gut microbiota composition and function can lead to dysbiosis, which has been linked to the etiology of multiples GI [51] and non-GI diseases such as anxiety, depression [52], autism [53], spectrum disorders [54], AD [55], and for the interest of this review, PD…”
BackgroundPathogenesis of Parkinson disease—the gut–brain axis and environmental factors
Klingelhoefer, L., & Reichmann, H. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.197 · Cited by 598
The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?
Houser, M. C., & Tansey, M. G. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-016-0002-0 · Cited by 588 · cited 2×
“of chronic intestinal inflammation in some PD patients [171,172] leading to the hypothesis that intestinal and peripheral inflammation contribute to neuroinflammation aggravating the progression of the disease [173].”
BackgroundTansey, M. G., McCoy, M. K., & Frank-Cannon, T. C. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.07.004 · Cited by 583 · cited 1×
“PD is not considered an immune disease, but inflammation and neuroinflammation are important players in the etiology and/or the progression of the disease [160,161].”
BackgroundHamaker, B. R., & Tuncil, Y. E. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.07.028 · Cited by 580
The Genus Enterococcus: Between Probiotic Potential and Safety Concerns—An Update
Hanchi, H., Mottawea, W., Sebei, K., & Hammami, R. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01791 · Cited by 569 · cited 1×
“Importantly, some Enterococcus strains are included nowadays as food supplements in several probiotics preparations [75,267], and this should be considered in the management of PD patients.”
BackgroundMartinez‐Martin, P., Schapira, A. H. V., Stocchi, F., Sethi, K., Odin, P., MacPhee, G., Brown, R. G., Naidu, Y., Clayton, L., Abe, K., et al. (2007) · Movement Disorders · doi:10.1002/mds.21586 · Cited by 554
Heintz‐Buschart, A., Pandey, U., Wicke, T., Sixel‐Döring, F., Janzen, A., Sittig‐Wiegand, E., Trenkwalder, C., Oertel, W. H., Mollenhauer, B., & Wilmes, P. (2018) · Movement Disorders · doi:10.1002/mds.27105 · Cited by 554 · cited 1×
“Verrucomicrobia Verrucomicrobiaceae 8 0 [60,98,101,103,105,106,109,119]”
Short-Chain Fatty Acids Regulate the Enteric Neurons and Control Gastrointestinal Motility in Rats
Soret, R., Chevalier, J., De Coppet, P., Poupeau, G., Derkinderen, P., Segain, J. P., & Neunlist, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.053 · Cited by 530 · cited 1×
“They have the ability to directly affect GI physiology and the intestinal barrier function, as well as to keep digestive structures in optimal condition and have a role in peristalsis [126,127].”
BackgroundThe genetics of Parkinson disease
Deng, H., Wang, P., & Jankovic, J. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2017.12.007 · Cited by 530
Effects of Psychological, Environmental and Physical Stressors on the Gut Microbiota
Karl, J. P., Hatch, A. M., Arcidiacono, S. M., Pearce, S. C., Pantoja-Feliciano, I. G., Doherty, L. A., & Soares, J. W. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02013 · Cited by 530 · cited 1×
“However, stress, antibiotics, environmental factors, infections, diet, lifestyle, and geography are factors known to influence, alter and modify gut microbiota composition [46].”
BackgroundIntestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease
Hasegawa, S., Goto, S., Tsuji, H., Okuno, T., Asahara, T., Nomoto, K., Shibata, A., Fujisawa, Y., Minato, T., Okamoto, A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0142164 · Cited by 523 · cited 3×
“Actinobacteria Bifidobacteriaceae Bifidobacterium 6 2 [95,97,98,100,102,107,111,119]”
Developing a new class of engineered live bacterial therapeutics to treat human diseases
Charbonneau, M. R., Isabella, V. M., Li, N., & Kurtz, C. B. (2020) · Nature Communications · doi:10.1038/s41467-020-15508-1 · Cited by 523
van Kessel, S. P., Frye, A. K., El-Gendy, A. O., Castejon, M., Keshavarzian, A., van Dijk, G., & El Aidy, S. (2019) · Nature Communications · doi:10.1038/s41467-019-08294-y · Cited by 521 · cited 1×
“In addition, they reported that the relative abundance of tyrDC gene in stool samples from PD patients was positively correlated with higher daily L-dopa dosage requirement [265].”
BackgroundOttman, N., Reunanen, J., Meijerink, M., Pietilä, T. E., Kainulainen, V., Klievink, J., Huuskonen, L., Aalvink, S., Skurnik, M., Boeren, S., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0173004 · Cited by 520 · cited 5×
“Evidence from human studies reporting that TLR2 and TLR4 expression is increased in blood and brain samples of PD patients [180], and from animal studies in TLR4-KO mice treated with rotenone [172], strengthen the important role that TLR4 may play in intestinal and brain inflammation.”
BackgroundInfluentialParkinson’s Disease: Etiology, Neuropathology, and Pathogenesis
John van Geest Centre for Brain Repair, D. O. C. N., Kouli, A., Torsney, K. M., Department of Medicine for the Elderly, C. U. H. N. F. T., Clinical Gerontology Unit, D. O. P. H. A. P. C., Kuan, W.-L., & John van Geest Centre for Brain Repair, D. O. C. N. (2018) · Parkinson’s Disease: Pathogenesis and Clinical Aspects · doi:10.15586/codonpublications.parkinsonsdisease.2018.ch1 · Cited by 507
Watson, H., Mitra, S., Croden, F. C., Taylor, M., Wood, H. M., Perry, S. L., Spencer, J. A., Quirke, P., Toogood, G. J., Lawton, C. L., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314968 · Cited by 506
Intestinal infection triggers Parkinson's disease-like symptoms in Pink1(-/-) mice
Matheoud, D., Cannon, T., Voisin, A., Penttinen, A.-M., Ramet, L., Fahmy, A. M., Ducrot, C., Laplante, A., Bourque, M.-J., Zhu, L., et al. (2019) · Nature · doi:10.1038/s41586-019-1405-y · Cited by 496 · cited 1×
“Finally, another study using mice lacking PINK1 demonstrated that intestinal infection with Gram-negative bacteria caused a decrease in the density of dopaminergic axonal varicosities in the striatum and impairment in some motor functions [93].”
BackgroundAnalysis of Gut Microbiota in Patients with Parkinson’s Disease
Petrov, V. A., Saltykova, I. V., Zhukova, I. A., Alifirova, V. M., Zhukova, N. G., Dorofeeva, Y. B., Tyakht, A. V., Kovarsky, B. A., Alekseev, D. G., Kostryukova, E. S., et al. (2017) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-017-3700-7 · Cited by 487 · cited 4×
“Actinobacteria Bifidobacteriaceae Bifidobacterium 6 2 [95,97,98,100,102,107,111,119]”
InfluentialThe Impact of Western Diet and Nutrients on the Microbiota and Immune Response at Mucosal Interfaces
Statovci, D., Aguilera, M., MacSharry, J., & Melgar, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00838 · Cited by 482
Motor symptoms in Parkinson’s disease: A unified framework
Moustafa, A. A., Chakravarthy, S., Phillips, J. R., Gupta, A., Keri, S., Polner, B., Frank, M. J., & Jahanshahi, M. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.07.010 · Cited by 481
Parkinson's Disease and the Environment
Ball, N., Teo, W.-P., Chandra, S., & Chapman, J. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00218 · Cited by 480 · cited 1×
“Epidemiological and experimental evidence suggest that environmental factors might have an important role in triggering or propagating the pathology [64,65].”
BackgroundNonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
Chen, H., Jacobs, E., Schwarzschild, M. A., McCullough, M. L., Calle, E. E., Thun, M. J., & Ascherio, A. (2005) · Annals of Neurology · doi:10.1002/ana.20682 · Cited by 472
The effects of probiotics on depressive symptoms in humans: a systematic review
Wallace, C. J. K., & Milev, R. (2017) · Annals of General Psychiatry · doi:10.1186/s12991-017-0138-2 · Cited by 471
Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease
Lin, C.-H., Chen, C.-C., Chiang, H.-L., Liou, J.-M., Chang, C.-M., Lu, T.-P., Chuang, E. Y., Tai, Y.-C., Cheng, C., Lin, H.-Y., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1528-y · Cited by 469
Role of TLR4 in the gut-brain axis in Parkinson's disease: A translational study from men to mice
Perez-Pardo, P., Dodiya, H. B., Engen, P. A., Forsyth, C. B., Huschens, A. M., Shaikh, M., Voigt, R. M., Naqib, A., Green, S. J., Kordower, J. H., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316844 · Cited by 467 · cited 2×
“of chronic intestinal inflammation in some PD patients [171,172] leading to the hypothesis that intestinal and peripheral inflammation contribute to neuroinflammation aggravating the progression of the disease [173].”
BackgroundLucas, K., & Maes, M. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8425-7 · Cited by 466 · cited 4×
“A. muciniphila is capable of inducing a wide range of immune-modulatory responses in vitro including induction of cytokine production and activation of Toll-like receptors 2 and 4 (TLR2 and TLR4) [136], indicating that it cannot be strictly defined as anti- or pro- inflammatory, but may instead have a more complex rol…”
BackgroundInfluentialGut microbiota: A player in aging and a target for anti-aging intervention
Vaiserman, A. M., Koliada, A. K., & Marotta, F. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.01.001 · Cited by 465 · cited 3×
“At the phylum level, the increase of Proteobacteria, Actinobacteria, and Verrucomicrobia was reported in 4, 5, and 6 studies, respectively (Table 1).”
BackgroundInfluentialLRRK2 Inhibition Attenuates Microglial Inflammatory Responses
Moehle, M. S., Webber, P. J., Tse, T., Sukar, N., Standaert, D. G., DeSilva, T. M., Cowell, R. M., & West, A. B. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5601-11.2012 · Cited by 463 · cited 1×
“LRRK2 is highly expressed in both innate and adaptive immune cells, supporting the idea of its central role in immune responses [194].”
BackgroundChen, S. G., Stribinskis, V., Rane, M. J., Demuth, D. R., Gozal, E., Roberts, A. M., Jagadapillai, R., Liu, R., Choe, K., Shivakumar, B., et al. (2016) · Scientific Reports · doi:10.1038/srep34477 · Cited by 463 · cited 1×
“Emerging evidence has shown that protein nucleation and aggregation may be influenced by an extracellular amyloid protein called “curli” secreted by Escherichia Coli [80] inducing neuronal deposition of a-syn in the gut and promoting neuroinflammation.”
BackgroundEngineering bacteria for diagnostic and therapeutic applications
Riglar, D. T., & Silver, P. A. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.172 · Cited by 460
The NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453 · cited 1×
“Moreover, they suggest that minocycline may be of concern when considering a long-term study [216,217].”
BackgroundVagotomy and Parkinson disease: A Swedish register–based matched-cohort study
Liu, B., Fang, F., Pedersen, N. L., Tillander, A., Ludvigsson, J. F., Ekbom, A., Svenningsson, P., Chen, H., & Wirdefeldt, K. (2017) · Neurology · doi:10.1212/wnl.0000000000003961 · Cited by 447
Akkermansia muciniphila in the Human Gastrointestinal Tract: When, Where, and How?
Geerlings, S. Y., Kostopoulos, I., De Vos, W. M., & Belzer, C. (2018) · Microorganisms · doi:10.3390/microorganisms6030075 · Cited by 446
Prebiotics: why definitions matter
Hutkins, R. W., Krumbeck, J. A., Bindels, L. B., Cani, P. D., Fahey, G., Goh, Y. J., Hamaker, B., Martens, E. C., Mills, D. A., Rastal, R. A., et al. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2015.09.001 · Cited by 437
Modeling Parkinson’s Disease With the Alpha-Synuclein Protein
Gómez-Benito, M., Granado, N., García-Sanz, P., Michel, A., Dumoulin, M., & Moratalla, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00356 · Cited by 437 · cited 1×
“PD neuropathology is also characterized by the presence of cytoplasmic inclusions enriched in aggregated forms of α-synuclein (α-syn) called Lewy bodies (LB) [32].”
BackgroundParamsothy, S., Paramsothy, R., Rubin, D. T., Kamm, M. A., Kaakoush, N. O., Mitchell, H. M., & Castaño-Rodríguez, N. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx063 · Cited by 436
Aho, V. T. E., Houser, M. C., Pereira, P. A. B., Chang, J., Rudi, K., Paulin, L., Hertzberg, V., Auvinen, P., Tansey, M. G., & Scheperjans, F. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00427-6 · Cited by 435
Olfaction in Parkinson's disease and related disorders
Doty, R. L. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.026 · Cited by 431 · cited 1×
“However, clinical features include non-motor symptoms such as depression [9], REM-sleep behavior disorder [10,11], autonomic dysfunction [12], olfactory disruption [13], and constipation [14,15], among others.”
BackgroundEngineered bacteria can function in the mammalian gut long-term as live diagnostics of inflammation
Riglar, D. T., Giessen, T. W., Baym, M., Kerns, S. J., Niederhuber, M. J., Bronson, R. T., Kotula, J. W., Gerber, G. K., Way, J. C., & Silver, P. A. (2017) · Nature Biotechnology · doi:10.1038/nbt.3879 · Cited by 426
van Passel, M. W. J., Kant, R., Zoetendal, E. G., Plugge, C. M., Derrien, M., Malfatti, S. A., Chain, P. S. G., Woyke, T., Palva, A., de Vos, W. M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016876 · Cited by 423 · cited 1×
“muciniphila), a gram-negative bacteria located mainly in the mucus layer of the intestinal epithelium and producing mucin-degrading enzymes, that has an important role in maintaining intestinal barrier homeostasis and exerts competitive inhibition on other pathogenic bacteria that degrade the mucin [130,131].”
BackgroundXu, Y., Wang, N., Tan, H.-Y., Li, S., Zhang, C., & Feng, Y. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00219 · Cited by 420
Inflammatory Process in Parkinsons Disease: Role for Cytokines
Nagatsu, T., & Sawada, M. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053381620 · Cited by 412
Alteration of the fecal microbiota in Chinese patients with Parkinson’s disease
Qian, Y., Yang, X., Xu, S., Wu, C., Song, Y., Qin, N., Chen, S.-D., & Xiao, Q. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.02.016 · Cited by 409 · cited 2×
“Actinobacteria Bifidobacteriaceae Bifidobacterium 6 2 [95,97,98,100,102,107,111,119]”
Probiotics and the Gut Immune System: Indirect Regulation
La Fata, G., Weber, P., & Mohajeri, M. H. (2018) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-017-9322-6 · Cited by 407 · cited 1×
“In addition, they increased the expression of tight junction proteins and upregulated mucus secretion [147].”
BackgroundLi, W., Wu, X., Hu, X., Wang, T., Liang, S., Duan, Y., Jin, F., & Qin, B. (2017) · Science China Life Sciences · doi:10.1007/s11427-016-9001-4 · Cited by 406 · cited 2×
“Firmicutes Lachnospiraceae Blautia 0 6 [95,98,99,101,111,119]”
Gut-seeded α-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice
Challis, C., Hori, A., Sampson, T. R., Yoo, B. B., Challis, R. C., Hamilton, A. M., Mazmanian, S. K., Volpicelli-Daley, L. A., & Gradinaru, V. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0589-7 · Cited by 405
Depression and Parkinson’s Disease: Current Knowledge
Marsh, L. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0409-5 · Cited by 404 · cited 1×
“However, clinical features include non-motor symptoms such as depression [9], REM-sleep behavior disorder [10,11], autonomic dysfunction [12], olfactory disruption [13], and constipation [14,15], among others.”
BackgroundSystematic review with meta-analysis: The efficacy of probiotics in inflammatory bowel disease
Derwa, Y., Gracie, D. J., Hamlin, P. J., & Ford, A. C. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14203 · Cited by 393
Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism
Barichella, M., Severgnini, M., Cilia, R., Cassani, E., Bolliri, C., Caronni, S., Ferri, V., Cancello, R., Ceccarani, C., Faierman, S., et al. (2019) · Movement Disorders · doi:10.1002/mds.27581 · Cited by 393 · cited 3×
“Actinobacteria Bifidobacteriaceae 5 0 [98,103,104,107,119]”
Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT
Barichella, M., Pacchetti, C., Bolliri, C., Cassani, E., Iorio, L., Pusani, C., Pinelli, G., Privitera, G., Cesari, I., Faierman, S. A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003127 · Cited by 390
Techniques used to characterize the gut microbiota: a guide for the clinician
Fraher, M. H., O'Toole, P. W., & Quigley, E. M. M. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.44 · Cited by 385 · cited 1×
“The use of shotgun metagenomics to carry out non-targeted sequencing of the gut microbiota community and the use of 16S rRNA gene amplicon surveys to study the bacterial and archaeal community structures have become popular and accessible techniques for clinical researchers [94].”
MethodFecal Microbiota Transplantation for Clostridium difficile Infection: A Systematic Review
Drekonja, D., Reich, J., Gezahegn, S., Greer, N., Shaukat, A., MacDonald, R., Rutks, I., & Wilt, T. J. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2693 · Cited by 371
Meta‐Analysis of Gut Dysbiosis in Parkinson's Disease
Nishiwaki, H., Ito, M., Ishida, T., Hamaguchi, T., Maeda, T., Kashihara, K., Tsuboi, Y., Ueyama, J., Shimamura, T., Mori, H., et al. (2020) · Movement Disorders · doi:10.1002/mds.28119 · Cited by 370 · cited 1×
“Nevertheless, an increased abundance of genus Akkermansia and an increased intestinal permeability in PD may expose the intestinal neural plexus directly to oxidative stress or toxins [114].”
BackgroundSriram, K., Matheson, J. M., Benkovic, S. A., Miller, D. B., Luster, M. I., & O'Callaghan, J. P. (2002) · The FASEB Journal · doi:10.1096/fj.02-0216fje · Cited by 362
Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression
Aho, V. T. E., Pereira, P. A. B., Voutilainen, S., Paulin, L., Pekkonen, E., Auvinen, P., & Scheperjans, F. (2019) · eBioMedicine · doi:10.1016/j.ebiom.2019.05.064 · Cited by 361 · cited 3×
“Actinobacteria Bifidobacteriaceae 5 0 [98,103,104,107,119]”
LRRK2 kinase in Parkinson's disease
Alessi, D. R., & Sammler, E. (2018) · Science · doi:10.1126/science.aar5683 · Cited by 345 · cited 1×
“Thus, LRRK2 might regulate inflammatory responses in the intestine and mutations may have multiple downstream effects [195].”
BackgroundEffect of probiotics on central nervous system functions in animals and humans: a systematic review
Wang, H., Lee, I.-S., Braun, C., & Enck, P. (2016) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm16018 · Cited by 334
[Epidemiology of Parkinson disease].
Domínguez Carmona, M. (1989) · PubMed · Cited by 330
Li, N., Wang, Q., Wang, Y., Sun, A., Lin, Y., Jin, Y., & Li, X. (2019) · Stress · doi:10.1080/10253890.2019.1617267 · Cited by 327
Probiotics, Prebiotics and Synbiotics
Hawrelak, J. (2007) · eCite Digital Repository (University of Tasmania) · Cited by 320
Gut microbiota in Parkinson disease in a northern German cohort
Hopfner, F., Künstner, A., Müller, S. H., Künzel, S., Zeuner, K. E., Margraf, N. G., Deuschl, G., Baines, J. F., & Kuhlenbäumer, G. (2017) · Brain Research · doi:10.1016/j.brainres.2017.04.019 · Cited by 318
The genetics and neuropathology of Parkinson’s disease
Houlden, H., & Singleton, A. B. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1013-5 · Cited by 316
Carballo-Carbajal, I., Laguna, A., Romero-Giménez, J., Cuadros, T., Bové, J., Martinez-Vicente, M., Parent, A., Gonzalez-Sepulveda, M., Peñuelas, N., Torra, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08858-y · Cited by 316 · cited 1×
“regions has also been reported [28–30], preferentially occurring within neurons that contain the dark-brown cytoplasmic pigment neuromelanin (NM) [29,31].”
BackgroundSelf-citationNeuronal vulnerability, pathogenesis, and Parkinson's disease
Sulzer, D., & Surmeier, D. J. (2013) · Movement Disorders · doi:10.1002/mds.25095 · Cited by 315
Triggers, Facilitators, and Aggravators: Redefining Parkinson’s Disease Pathogenesis
Johnson, M. E., Stecher, B., Labrie, V., Brundin, L., & Brundin, P. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.09.007 · Cited by 310
Cytokines in Parkinson’s disease
Nagatsu, T., Mogi, M., Ichinose, H., & Togari, A. (2000) · Advances in Research on Neurodegeneration · doi:10.1007/978-3-7091-6284-2_12 · Cited by 308
Engineering bacterial thiosulfate and tetrathionate sensors for detecting gut inflammation
Daeffler, K. N., Galley, J. D., Sheth, R. U., Ortiz‐Velez, L. C., Bibb, C. O., Shroyer, N. F., Britton, R. A., & Tabor, J. J. (2017) · Molecular Systems Biology · doi:10.15252/msb.20167416 · Cited by 301
Van Den Berge, N., Ferreira, N., Gram, H., Mikkelsen, T. W., Alstrup, A. K. O., Casadei, N., Tsung-Pin, P., Riess, O., Nyengaard, J. R., Tamgüney, G., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02040-w · Cited by 300
Incidence and remaining lifetime risk of Parkinson disease in advanced age
Driver, J. A., Logroscino, G., Gaziano, J. M., & Kurth, T. (2009) · Neurology · doi:10.1212/01.wnl.0000341769.50075.bb · Cited by 298 · cited 1×
“One of the main risk factors for PD is aging [150].”
BackgroundChanges of colonic bacterial composition in Parkinson's disease and other neurodegenerative diseases
Gerhardt, S., & Mohajeri, M. H. (2018) · Nutrients · doi:10.3390/nu10060708 · Cited by 298 · cited 1×
“Its abundance in the human intestinal tract is inversely correlated to several disease states such as obesity [132–134], while an increase of the relative abundance is consistently reported in PD patients [49,135].”
BackgroundStructural alterations of the intestinal epithelial barrier in Parkinson’s disease
Clairembault, T., Leclair-Visonneau, L., Coron, E., Bourreille, A., Le Dily, S., Vavasseur, F., Heymann, M.-F., Neunlist, M., & Derkinderen, P. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0196-0 · Cited by 291 · cited 1×
“Interestingly, some studies report alterations in the intestinal epithelial barrier [169,170] and the presence”
BackgroundGut Microbiota and Metabolome Alterations Associated with Parkinson’s Disease
Vascellari, S., Palmas, V., Melis, M., Pisanu, S., Cusano, R., Uva, P., Perra, D., Madau, V., Sarchioto, M., Oppo, V., et al. (2020) · mSystems · doi:10.1128/msystems.00561-20 · Cited by 286 · cited 4×
“Actinobacteria Bifidobacteriaceae 5 0 [98,103,104,107,119]”
InfluentialReview: Deep brain stimulation in Parkinson’s disease
Groiss, S. J., Wojtecki, L., Südmeyer, M., & Schnitzler, A. (2009) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285609339382 · Cited by 280
Minocycline as a Neuroprotective Agent
Stirling, D. P., Koochesfahani, K. M., Steeves, J. D., & Tetzlaff, W. (2005) · The Neuroscientist · doi:10.1177/1073858405275175 · Cited by 279 · cited 1×
“Together, the available studies suggest that minocycline inhibits microglial activation through p38 MAPK pathway, which regulates the release of pro-inflammatory factors from activated microglia [213,214].”
BackgroundCD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease
Galiano-Landeira, J., Torra, A., Vila, M., & Bové, J. (2020) · Brain · doi:10.1093/brain/awaa269 · Cited by 267 · cited 1×
“In addition, infiltration and accumulation of peripheral immune cells are also found in affected brain regions in PD patients [168].”
BackgroundSun, J., Li, H., Jin, Y., Yu, J., Mao, S., Su, K.-P., Ling, Z., & Liu, J. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.10.014 · Cited by 264 · cited 1×
“They associated the neuroprotective mechanism with the glucagon-like peptide-1 (GLP-1/GLP-1 receptor) pathway [249].”
BackgroundParkinsonian signs and substantia nigra neuron density in decendents elders without PD
Ross, G. W., Petrovitch, H., Abbott, R. D., Nelson, J., Markesbery, W., Davis, D., Hardman, J., Launer, L., Masaki, K., Tanner, C. M., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20226 · Cited by 260 · cited 1×
“, rigidity, movement slowness, resting tremor, among others [4–6]), which is first noticeable when there is already 40–60% neuronal loss in the substantia nigra (SN) [7,8].”
BackgroundDietary fatty acids and the risk of Parkinson disease: The Rotterdam Study
de Lau, L. M. L., Bornebroek, M., Witteman, J. C. M., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2005) · Neurology · doi:10.1212/01.wnl.0000166038.67153.9f · Cited by 259
Obrenovich, M. E. M. (2018) · Microorganisms · doi:10.3390/microorganisms6040107 · Cited by 255
Pavlov, V. A., & Tracey, K. J. (2015) · Immunologic Research · doi:10.1007/s12026-015-8718-1 · Cited by 254 · cited 1×
“However, the introduction of external substances or pathogens and gut dysbiosis can both lead to increased gut inflammation, thus affecting intestinal homeostasis and altering CNS function via the release of neurotransmitters and cytokines [173,176,177].”
BackgroundGut microbiota in patients with Parkinson's disease in southern China
Lin, A., Zheng, W., He, Y., Tang, W., Wei, X., He, R., Huang, W., Su, Y., Huang, Y., Zhou, H., et al. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.05.007 · Cited by 253 · cited 2×
“Actinobacteria Bifidobacteriaceae 5 0 [98,103,104,107,119]”
Wallen, Z. D., Appah, M., Dean, M. N., Sesler, C. L., Factor, S. A., Molho, E., Zabetian, C. P., Standaert, D. G., & Payami, H. (2020) · npj Parkinson s Disease · doi:10.1038/s41531-020-0112-6 · Cited by 252 · cited 5×
“Firmicutes Lachnospiraceae Blautia 0 6 [95,98,99,101,111,119]”
BackgroundInfluentialLevodopa in the treatment of Parkinson’s disease: an old drug still going strong
Antonini, A. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s6456 · Cited by 250
Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies
Palma, J., & Kaufmann, H. (2018) · Movement Disorders · doi:10.1002/mds.27344 · Cited by 245 · cited 1×
“Thus, they are considered as valuable markers of early disease stages [18].”
BackgroundThe lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery
Dutta, G., Zhang, P., & Liu, B. (2008) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00616.x · Cited by 235
Fecal Microbiota Transplantation: An Update on Clinical Practice
Kim, K. O., & Gluck, M. (2019) · Clinical Endoscopy · doi:10.5946/ce.2019.009 · Cited by 233
Levodopa in the Treatment of Parkinson's Disease: Current Status and New Developments
Salat, D., & Tolosa, E. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130186 · Cited by 232 · cited 1×
“L-dopa is usually administered in combination with an inhibitor of its peripheral conversion to dopamine (carbidopa or benserazide) [37].”
BackgroundFecal microbiota transplantation broadening its application beyond intestinal disorders
Xu, M.-Q. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i1.102 · Cited by 231
Gut microbiota: Implications in Parkinson's disease
Parashar, A., & Udayabanu, M. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.02.002 · Cited by 230
Baldini, F., Hertel, J., Sandt, E., Thinnes, C. C., Neuberger-Castillo, L., Pavelka, L., Betsou, F., Krüger, R., Thiele, I., on behalf of the NCER-PD Consortium, et al. (2020) · BMC Biology · doi:10.1186/s12915-020-00775-7 · Cited by 230 · cited 1×
“These discrepancies make it difficult to reach a general agreement and determine which is the PD dysbiotic profile and which are the exact alterations in metabolic pathways [49,149].”
BackgroundConstipation preceding Parkinson's disease: a systematic review and meta-analysis
Adams-Carr, K. L., Bestwick, J. P., Shribman, S., Lees, A., Schrag, A., & Noyce, A. J. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-311680 · Cited by 228 · cited 1×
“However, clinical features include non-motor symptoms such as depression [9], REM-sleep behavior disorder [10,11], autonomic dysfunction [12], olfactory disruption [13], and constipation [14,15], among others.”
Probiotics for Constipation in Parkinson Disease: A Randomized Placebo-Controlled Study
Tan, A. H., Lim, S.-Y., Chong, K. K., A Manap, M. A. A., Hor, J. W., Lim, J. L., Low, S. C., Chong, C. W., Mahadeva, S., & Lang, A. E. (2021) · Neurology · doi:10.1212/wnl.0000000000010998 · Cited by 226
Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems
Brichta, L., Greengard, P., & Flajolet, M. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.06.003 · Cited by 223 · cited 20×
“Related with this study, a different group described another possible pathway for gut bacterial L-dopa metabolism.”
BackgroundInfluentialYou Are What You Host: Microbiome Modulation of the Aging Process
Heintz, C., & Mair, W. (2014) · Cell · doi:10.1016/j.cell.2014.01.025 · Cited by 222
Rifampicin Inhibits α-Synuclein Fibrillation and Disaggregates Fibrils
Li, J., Zhu, M., Rajamani, S., Uversky, V. N., & Fink, A. L. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.08.025 · Cited by 218 · cited 1×
“In vitro, it binds α-syn and inhibits its fibrillation by stabilizing the monomeric form of the protein as well as disaggregates the existing pre-formed fibrils [229].”
BackgroundDysbiosis of gut microbiota in a selected population of Parkinson's patients
Pietrucci, D., Cerroni, R., Unida, V., Farcomeni, A., Pierantozzi, M., Mercuri, N. B., Biocca, S., Stefani, A., & Desideri, A. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.06.003 · Cited by 217 · cited 2×
“Verrucomicrobia Verrucomicrobiaceae 8 0 [60,98,101,103,105,106,109,119]”
Srivastav, S., Neupane, S., Bhurtel, S., Katila, N., Maharjan, S., Choi, H., Hong, J. T., & Choi, D.-Y. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.03.021 · Cited by 212 · cited 4×
“• Neuroprotective effects on dopaminergic cells against MPTP and Rotenone-induced toxicity: o Upregulate expression of BDNF and GDNF o Downregulate expression of MAO-B o Increase levels of butyrate • Prevented behavioral impairment [246]”
BackgroundInfluentialMind-altering with the gut: Modulation of the gut-brain axis with probiotics
Kim, N., Yun, M., Oh, Y. J., & Choi, H.-J. (2018) · Journal of Microbiology · doi:10.1007/s12275-018-8032-4 · Cited by 210
Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates
Arotcarena, M.-L., Dovero, S., Prigent, A., Bourdenx, M., Camus, S., Porras, G., Thiolat, M.-L., Tasselli, M., Aubert, P., Kruse, N., et al. (2020) · Brain · doi:10.1093/brain/awaa096 · Cited by 210 · cited 1×
“This hypothesis is supported by data from rodent and non-human primate experimental models [69], where different forms of α-syn were transported via the vagus nerve and reached the DMNV in the brainstem after injection into the intestinal wall [66,70–74].”
Result(2011) · PubMed · Cited by 207
Commensal bacteria direct selective cargo sorting to promote symbiosis
Zhang, Q., Pan, Y., Yan, R., Zeng, B., Wang, H., Zhang, X., Li, W., Wei, H., & Liu, Z. (2015) · Nature Immunology · doi:10.1038/ni.3233 · Cited by 206
da Silva, T. M., Munhoz, R. P., Alvarez, C., Naliwaiko, K., Kiss, Á., Andreatini, R., & Ferraz, A. C. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.03.008 · Cited by 205
Probiotic Bacillus subtilis protects against α-synuclein aggregation in C. elegans
Goya, M. E., Xue, F., Sampedro-Torres-Quevedo, C., Arnaouteli, S., Riquelme-Dominguez, L., Romanowski, A., Brydon, J., Ball, K. L., Stanley-Wall, N. R., & Doitsidou, M. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.078 · Cited by 205 · cited 2×
“elegans) model of synucleinopathy • Inhibited α-syn aggregation • Cleared preformed aggregates [245]”
BackgroundThe Gut-Brain Axis in Parkinson’s Disease: Possibilities for Food-Based Therapies
Perez-Pardo, P., Kliest, T., Dodiya, H. B., Broersen, L. M., Garssen, J., Keshavarzian, A., & Kraneveld, A. D. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.042 · Cited by 203
Fecal microbiota transplantation to treat Parkinson's disease with constipation: A case report
Huang, H., Xu, H., Luo, Q., He, J., Li, M., Chen, H., Tang, W., Nie, Y., & Zhou, Y. (2019) · Medicine · doi:10.1097/md.0000000000016163 · Cited by 201
Cited by
The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders
Socała, K., Doboszewska, U., Szopa, A., Serefko, A., Włodarczyk, M., Zielińska, A., Poleszak, E., Fichna, J., & Wlaź, P. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105840 · Cited by 857
A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders
Sorboni, S. G., Moghaddam, H. S., Jafarzadeh-Esfehani, R., & Soleimanpour, S. (2022) · Clinical Microbiology Reviews · doi:10.1128/cmr.00338-20 · Cited by 522
Therapeutic Benefits and Dietary Restrictions of Fiber Intake: A State of the Art Review
Ioniță-Mîndrican, C.-B., Ziani, K., Mititelu, M., Oprea, E., Neacșu, S. M., Moroșan, E., Dumitrescu, D.-E., Roșca, A. C., Drăgănescu, D., & Negrei, C. (2022) · Nutrients · doi:10.3390/nu14132641 · Cited by 251
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies
Zhang, X., Tang, B., & Guo, J. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00392-8 · Cited by 187
“Microbial therapy can improve the clinical manifestations of PD [43].”
BackgroundGut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease
Zhu, M., Liu, X., Ye, Y., Yan, X., Cheng, Y., Zhao, L., Chen, F., & Ling, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.937555 · Cited by 177
Metadata
- Authors
- Lorente-Picón, M., & Laguna, A.
- Affiliations
- Neurodegenerative Diseases Research Group, Vall d’Hebron Research Institute (VHIR)-Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain
- Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
- Corresponding author
- Laguna, Ariadna
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2021-03-15
- Volume
- 11
- Issue
- 3
- Pages
- 433
- ISSN
- 2218-273X (ISSN-L)
- PMC
- PMC7998286
- OpenAlex
- W3139351167
- Cited by
- 69
- References
- 366
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 10 · 2023: 13 · 2022: 17 · 2021: 9
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomolecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- La Caixa Banking Foundation (LCF/BQ/PR19/11700005)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- Parkinson's disease, gut microbiota, gut-brain axis, disease-modifying therapy, probiotics, prebiotics, synbiotics, fecal microbiota transplantation, live biotherapeutic products, antibiotics, dietary intervention, motor symptoms, neurodegeneration
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Brain, Humans, Parkinson Disease, Phylogeny, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.